Her Majesty the Queen Sofia of Spain has made today a private visit to the Laboratory of Molecular and Cellular Biomedicine of the University of the Balearic Islands. The research group, led by Dr. Pablo V. Escribá and Dr. Xavier Busquets, Laminar Pharma’s main scientific promoters, togheter with the resto of the scientific team, presented the latest advances on Alzheimer’s Disease (AD) and other CNS-related diseases research. The group is investigating a derivative of DHA (HDHA) that crosses the blood brain barrier and which has shown a marked capacity to improve cognitive scores in two experimental animal models of Alzheimer Disease. These results have been published in the prestigious scientific journal Biochimica et Biophysica Acta-Biomembranes, which in June 2014 dedicated an special issue to the Membrane Lipid Therapy, including the results of the research conducted with HDHA in AD.

One of the main objectives of the Queen Sofia Foundation (where Queen Sofia acts as the Chief Executive Officer) is the promotion of research in Alzheimer’s Disease through the Alzheimer Project campaigns, aimed at raising awareness within the Spanish society on the need to increase the research in this devastating disease.